Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05309304 · ClinicalTrials.gov registry record · Phase 1
Cefazolin PK Study 3g vs 2g
A Phase 1 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05309304 is a Phase 1 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 24 participants.
The verdict
NCT05309304, a Phase 1 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.
Interventions
- DRUG Cefazolin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05309304
The ClinicalTrials.gov registry entry for NCT05309304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cefazolin is the first listed.
NCT05309304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05309304 about?
NCT05309304 is a clinical study titled "Cefazolin PK Study 3g vs 2g". Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 12...
What is the current status of trial NCT05309304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-02-14. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT05309304?
The interventions under investigation include: Cefazolin (DRUG).
Who is sponsoring clinical trial NCT05309304?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.